Scott Alexander critiques the FDA approval of esketamine for depression, discussing issues with drug development, efficacy, cost, and administration requirements.

Scott Alexander argues for the broader use of guidelines instead of simple recommendations in fields outside medicine, explaining their benefits and why they're underutilized.

Scott Alexander critically examines a major meta-analysis on antidepressant efficacy, noting potential biases and comparing its surprising drug rankings to his own previous analysis.

Scott provides answers to a dermatology quiz, discussing skin cancer risks, a quiz correction, and the surprising effectiveness of Botox in treating depression.

Scott Alexander examines a study showing no significant difference between CBT and psychodynamic therapy, challenging the idea that CBT is superior and exploring the possibility that most psychotherapies work through non-specific factors.